Edwards Lifesciences–The FDA has approved the company's new heart valve designed to be used in patients suffering from aortic stenosis.
DSW–The shoe retailer's shares were upgraded by Goldman Sachs to "buy" from "neutral," calling it "best-in-class" and saying a recent drop in the stock's price puts it at an attractive entry point given its solid fundamentals.
Orbitz, Expedia–The two travel services providers are the recipients of bullish analyst comment this morning, with UBS issuing a "buy" rating on Orbitz in new coverage, while Susquehanna upgraded Expedia to "positive" from "neutral." UBS said Orbitz will benefit from an improving hotel segment as well as growth in its business-to-business operations, while Susquehanna called consensus estimates for Expedia "too low."
Domino's Pizza–Bank of America/Merrill Lynch downgraded Domino's to "underperform" from "neutral," saying the stock is still trading at multiples that are too rich despite a 10 percent drop from the stock's all-time high in March.
Korn/Ferry–The company earned 43 cents per share for its fourth quarter, beating estimates by four cents, with revenue exceeding estimates as well. The executive recruiter has expanded its revenue base through several acquisitions.
Wells Fargo, JPMorgan Chase–Both banks may fall below minimum capital thresholds dictated by new rules being formulated by regulators, according to a Reuters report.
AbbVie–The drug maker has gotten an accelerated European Union review for a new oral hepatitis C treatment, meaning it could be available in the EU by early in 2015. The FDA had previously granted fast-track review for the treatment.
Gentiva Health Services–Gentiva received an improved takeover bid from Kindred Healthcare, with Kindred raising its offer from $14 per share to $14.50. The higher bid values Gentiva at $573 million.
General Electric–The industrial giant' bid for the energy assets of France's Alstom is better for Alstom's shareholders than a competing bid by Siemens and Mitsubishi Heavy Industries, according to a Barclays report.
Wex –The company is buying rival payments processor Evolution1 for $532.5 million in cash. Evolution1 specializes in payment processing for the health care industry.
—By CNBC's Peter Schacknow
Questions? Comments? Email us at firstname.lastname@example.org